Regulated information August 23, 2012 <\/p>\n
TiGenix Business Update & Financial Highlights for the First Half of 2012 <\/p>\n
Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012. <\/p>\n
Business highlights <\/p>\n
Financial highlights <\/p>\n
\"The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy,\" says Eduardo Bravo, CEO of TiGenix. \"We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601.\" <\/p>\n
Business update <\/p>\n
Commercial roll-out of ChondroCelect continues to gain momentum <\/p>\n
ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive reimbursement in the Netherland per January 1, 2011. <\/p>\n
Discussions to obtain full national reimbursement keep advancing in Spain, France, and Germany. In addition to the recent important reimbursement success, the Company has obtained a positive decision in the Netherlands by one of the leading private healthcare insurance companies to make treatment with ChondroCelect compulsory for its insured, no longer reimbursing non-ATMP cartilage products. Similarly, two of the large private insurers in the UK expressed their intention to routinely reimburse ChondroCelect going forward. <\/p>\n<\/p>\n
Go here to see the original: Regulated information August 23, 2012 TiGenix Business Update & Financial Highlights for the First Half of 2012 Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012. Business highlights Financial highlights \"The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy,\" says Eduardo Bravo, CEO of TiGenix Continue reading
\nTiGenix : Business Update & Financial Highlights for the First Half of 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"